| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tiziana Life Sciences Ltd | Foralumab (Intranasal) - (Yale MS Center Study) | Non-active Secondary Progressive Multiple Sclerosis (na-SPMS) | Phase 2 | Ongoing | Intranasal | Neurology |
| Tiziana Life Sciences Ltd | Milciclib in combination with gemcitabine | Non-small cell lung cancer (NSCLC) | Phase 2 | Oral | Oncology | |
| Tiziana Life Sciences Ltd | Foralumab (Intranasal) | Alzheimer’s Disease | Phase 2 | Enrollment Initiation | Intranasal | Neurology |
| Tiziana Life Sciences Ltd | Foralumab | COVID-19 | Phase 2 | Intranasal | COVID-19 | |
| Tiziana Life Sciences Ltd | Foralumab | Long COVID-19 | Phase 2a | Ongoing | Intranasal | COVID-19 |
| Tiziana Life Sciences Ltd | Foralumab (Intranasal) | Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2a | Ongoing | Intranasal | Neurology |
| Tiziana Life Sciences Ltd | Foralumab (Intranasal) | Secondary Progressive Multiple Sclerosis (SPMS) | Phase 2a | Ongoing | Intranasal | Neurology |
| Tiziana Life Sciences Ltd | Foralumab | Non-active, secondary-progressive multiple sclerosis (na-SPMS) | Phase 2a | Data Released | Intranasal | Neurology |